Insulet PODD SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's SG&A?
- Insulet (PODD) reported SG&A of $317.2M in Q1 2026.
- How has Insulet's SG&A changed year-over-year?
- Insulet's SG&A increased by 21.7% year-over-year, from $260.7M to $317.2M.
- What is the long-term trend for Insulet's SG&A?
- Over 4 years (2021 to 2025), Insulet's SG&A has grown at a 25.7% compound annual growth rate (CAGR), from $466M to $1.17B.
- What does SG&A mean?
- The overhead costs of running the business, including sales, marketing, and corporate administration.
- How do you interpret SG&A?
- Lower SG&A as a percentage of revenue suggests improving operational efficiency and scalability.
- How does SG&A compare across companies?
- Varies based on the maturity of the sales force and the intensity of marketing required in the medical device sector.